Management 1x1 Series: James Lanthier, CEO of Mindset Pharma - The Future of Psychedelics

Grizzle Pod: Thematic Growth Investing

コンテンツは Grizzle によって提供されます。エピソード、グラフィック、ポッドキャストの説明を含むすべてのポッドキャストコンテンツは、Grizzle またはそのポッドキャストプラットフォームパートナーによって直接アップロードされ、提供されます。誰かがあなたの著作物をあなたの許可なく使用していると思われる場合は、ここで概説されているプロセスに従うことができますhttps://ja.player.fm/legal。

2y ago 28:32

M4A•エピソードのホーム

In our second episode of the Management 1x1 Series we are thrilled to have James Lanthier, CEO of Mindset Pharma join us. Mindset is one of the world's leading companies in the field of psychedelic medicines to treat neurological and psychiatric disorders. James brings a wealth of insight to the pod and breaks down the big picture of the true disruption happening in the psychedelics industry - enjoy the interview.

Segments:

0:40 What's the opportunity set and how disruptive are psychedelics?

4:58 Where are we in terms of cultural and medical acceptance of psychedelics?

9:26 Mindset Pharma's science driven focus in the sector

13:42 Understanding the process of enhancing 1st generation psychedelic drugs.

18:45 Mindset's partnership with big pharma - Otsuka Pharmaceuticals, understanding the validation and importance for the industry.

23:40 The asset light nature of the business model.

25:13 The outlook for the psychedelics industry and what separates winners from losers?

88 つのエピソード

#Trading #Business #Grizzle